Policymakers around the world continue to face unprecedented decisions about pharmaceuticals and the healthcare industry. With rapid industry innovation comes new challenges, unanswered questions and intense debates on pricing and regulation.
This month, the industry saw progression in rare disease education for policymakers, a spotlight on drug price transparency bills and pricing penalties, advancements in digital therapeutics, development in global HTA use and continued efforts to fight the COVID-19 pandemic.
Here are a few of this month’s top stories:
Pricentric INSIGHT: BeNeLuxA’s Push for Innovative Drug Price Reduction Sees Zolgensma, Vertex’s CF Portfolio in Firing Line
At the start of May, the Netherlands’ Zorginstituut (ZIN) advised the country’s Minister for Medical Care to only reimburse Novartis’ Zolgensma (onasemnogene abeparvovec) as part of the country’s basic package after a substantial price reduction and a potential performance-related payment plan.
Pricentric INSIGHT: Could Waiving Vaccine Patent Rights Help Us Win the Fight Against COVID-19?
On May 5, the Biden administration supported waiving intellectual property rights for COVID-19 vaccines in a surprise U-turn on its previous stance — the EU promptly followed suit by announcing it would be willing to discuss the idea, and China also recently expressed support for the notion.
Pricentric INSIGHT: Cell & Gene Collective Launches to Raise Awareness of Promises, Challenges of Cell, Gene Therapy
Astellas, bluebird bio, Bristol-Myers Squibb (BMS), Kite (a Gilead company) and Novartis have launched the Cell & Gene Collective to raise awareness of the promises and challenges of cell and gene therapies.
Read the latest Pricentric ONE by EVERSANA ™ newsletter for more on global pricing trends and happenings.
Download the full newsletter here!
Contact us with your questions and global pricing needs, and an expert will follow up shortly.
NAVLIN Price & Access Data is a powerful competitor intelligence tool that provides near real-time updates to drug price (list / net), reimbursement, tender and cost of treatment information at the indication level. Our…